|
ROCSAN trial (GINECO-EN203b/ENGOT-EN8): A multicentric randomized phase II/III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum based chemotherapy. |
|
Isabelle Laure Ray-Coquard |
Honoraria - Abbvie; Advaxis; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; DECIPHERA; Genmab; GlaxoSmithKline; MERSANA; MSD Oncology; OxOnc; Pfizer; PharmaMar; Roche; Tesaro |
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Deciphera; Genmab; GlaxoSmithKline; Mersana; Mersana; MSD Oncology; Pfizer; PharmaMar; Roche; Tesaro |
Research Funding - BMS; MSD Oncology |
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro |
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; French National Cancer Institute (INCA) |
|
|
Honoraria - AstraZeneca; Clovis Oncology |
Consulting or Advisory Role - Ability Pharma (Inst); AstraZeneca (Inst); BioCad; Clovis Oncology (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); MSD (Inst); Tesaro (Inst); zentalis |
Research Funding - GamaMabs Pharma (Inst); Inivata (Inst); Merus (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Tesaro |
|
|
Honoraria - AZD; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Lilly; Takeda |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - AstraZeneca; Tesaro/GSK (Inst) |
Travel, Accommodations, Expenses - Roche |
|
Anne-Claire Hardy-Bessard |
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Novartis; Pfizer; Roche; Seagen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; clovis oncology; Roche; Tesaro/GSK; Tesaro/GSK |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology (Inst); GlaxoSmithKline; MSD Oncology (Inst); Roche |
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar |
|
|
Consulting or Advisory Role - AstraZeneca |
|
|
Honoraria - AstraZeneca; MSD; pfizer; pharmamar; Roche; Tesaro |
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Pfizer; PharmaMar; Roche; tesaro |
Research Funding - AstraZeneca (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst) |
|
|
Honoraria - Abbvie; AstraZeneca; Clovis Oncology; GlaxoSmithKline; Roche; Roche; Tesaro |
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline |
Research Funding - AstraZeneca; Bayer; Roche |
Travel, Accommodations, Expenses - Clovis Oncology; Roche; Tesaro |
|
|
Honoraria - AstraZeneca; Janssen; Roche |
Research Funding - SERVIER |
Patents, Royalties, Other Intellectual Property - GlaxoSmithKline |
|
|
Patents, Royalties, Other Intellectual Property - Myriad Genetics |
|
|
Travel, Accommodations, Expenses - Leo Pharma; Novartis; Pfizer |
|
|
Honoraria - AstraZeneca; LEO Pharma; Roche; Tesaro/GSK |
Consulting or Advisory Role - AstraZeneca; Roche; Tesaro/GSK |
Travel, Accommodations, Expenses - AstraZeneca; LEO Pharma; Roche; Tesaro/GSK |